Clinical Trials Logo

Tobacco Use Disorder clinical trials

View clinical trials related to Tobacco Use Disorder.

Filter by:

NCT ID: NCT03496077 Completed - Smoking Clinical Trials

Addictive Potential of LCCs in Dual Users

Start date: August 28, 2018
Phase: N/A
Study type: Interventional

This study is about whether or not little cigars and cigarillos cause or maintain addiction, and if flavors, such as fruit, make them more addictive. The purpose of this study is to understand the addiction potential of little cigars and cigarillos compared to cigarettes in young adults who smoke both products. This study will also look at the differences between men and women. In the rest of this form, little cigars or cigarillos will be referred to as LCCs.

NCT ID: NCT03492463 Completed - Clinical trials for Nicotine Dependence, Cigarettes

The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products

ENDS-Switch
Start date: August 6, 2018
Phase: Phase 2
Study type: Interventional

This study plans to investigate whether using electronic cigarettes (e-cigarettes) or skin patches containing nicotine affects switching from smoking conventional combustible (burning) cigarettes.

NCT ID: NCT03473483 Withdrawn - Nicotine Dependence Clinical Trials

Cigarette Harm Reduction With Electronic Cigarette Use

NIDA-SREC
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.

NCT ID: NCT03471767 Completed - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 25, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

NCT ID: NCT03463837 Completed - Tobacco Use Clinical Trials

Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

Diamond
Start date: March 4, 2018
Phase: N/A
Study type: Interventional

The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using three JUUL 5% ENDS compared to smoking usual brands of combustible cigarettes and stopping smoking.

NCT ID: NCT03450941 Not yet recruiting - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

NCT ID: NCT03449017 Completed - Alcohol Abuse Clinical Trials

Reactions to E-cigs and Alcohol

Start date: March 24, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to 1) examine cognitive acuity following e-cig use (as compared to no e-cig use), 2) examine motor coordination following beer and e-cig use (as compared to beer consumption only).

NCT ID: NCT03442413 Active, not recruiting - Smoking, Tobacco Clinical Trials

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

Start date: June 28, 2018
Phase: Phase 1
Study type: Interventional

Physically healthy adult smokers may be eligible for this study. Volunteers may participate in this study if they are 18 - 65 years old. Subjects will participate in two separate 7-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight. The 2-[18F]-FA PET/CT brain scans will consist of an injection followed by an 7-hour infusion of 2-[18F]-FA. The scan session will begin at approximately 4 hours after the bolus injection. The PET/CT scan will occur in two segments. Starting at approximately 4 hours post bolus and infusion start, we will scan for approximately 90 minutes with a bolus injection of IV nicotine that will occur approximately 15 minutes into the scanning procedure. There will be a break in scanning of approximately 60 minutes, during which subjects will be allowed to get off the scanner and use the restroom, if necessary. The second scan segment will start at approximately 6.5 hours post bolus injection, t. This segment will last approximately 30 minutes. The pre and post nicotine images will be analyzed to evaluate for differences in receptor uptake after the nicotine "challenge". Subjects will have a structural Brain MRI performed within 1 year prior to study enrollment or subjects who have not had a Brain MRI that is deemed acceptable for use for this study will undergo a research Brain MRI after consent.

NCT ID: NCT03438188 Completed - Clinical trials for Nicotine Use Disorder

Neural Basis of Eating Behavior in Abstinent Smokers

SIT
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this research study is to better understand why people gain weight when they quit smoking by examining food intake and changes in brain activity in smokers when they are smoking as usual compared to when they have been deprived of cigarettes (i.e., have not smoked for 4 days) as compared to a non-smoker control group.

NCT ID: NCT03419741 Completed - Breast Cancer Clinical Trials

Brain Stimulation For Cancer Smokers

Start date: October 21, 2017
Phase: N/A
Study type: Interventional

Smoking cessation and relapse prevention represent and important opportunity to improve cancer survival rates, reduce the risk of cancer treatment complication, and improve the quality of life of patients with and survivors of cancer. Previous studies showed that repetitive TMS (rTMS) reduced cue craving to smoking and treat nicotine dependent smokers. Recently one study completed by our team demonstrated that 10 sessions of rTMS over the left dorsolateral prefrontal cortex (DLPFC) reduced cigarette consumption and cue craving, and also increased quitting rate on target quit date in nicotine dependent smokers. Thus, we propose conducting a controlled, double-blind trial comparing the effect of treatments of active rTMS and sham rTMS on cigarette abstinence days, cigarette consumption and smoking craving during a 7-days of quit attempt period in 20 nicotine-dependent patients with cancer. Specific aims are: Aim 1: Assess a feasibility of the rTMS for smoking cessation in cancer patients. Aim 2: Obtain preliminary estimates of whether one-week active rTMS of left DLPFC tends to be more efficacious than sham rTMS during a 7-days of quit attempt laboratory model period increasing abstinence days, and also decreasing cigarette consumption and cue-elicited craving in cancer patients with smoking.